Cystic Fibrosis Market to Showcase Growth at a CAGR of 9% During the Forecast Period (2022-2032) | DelveInsight – PR Newswire

The overall cystic fibrosis market is expected to surge due to the increasing prevalence of the disease and expected launch of emerging therapies including Ensifentrine, VX-121/TEZ/ VX561, and others in the forecasted period (20222032).

LAS VEGAS, Oct. 12, 2022 /PRNewswire/ --DelveInsight's Cystic Fibrosis Market Insights report includes a comprehensive understanding of current treatment practices, cystic fibrosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Takeaways from the Cystic Fibrosis Market Report

Discover which therapies are expected to grab the major cystic fibrosis market share @Cystic Fibrosis Market Report

Cystic Fibrosis Overview

Cystic fibrosis is a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. F508del is the most common variation reported globally, but there are over 2000 others, not all causing the disease.

The cystic fibrosis symptoms usually appear 6-8 months after birth, though this varies significantly from person to person. Cystic fibrosis symptoms vary with age and can affect different body parts. Newborn screening, a genetic test to look for a gene defect, and a blood test to look for pancreatic problems are two tests used for cystic fibrosis diagnosis. After initial testing, a sweat test can be performed to confirm the cystic fibrosis diagnosis.

Cystic Fibrosis Epidemiology Segmentation

DelveInsight estimates that there were approximately 65.5K diagnosed prevalent cases of cystic fibrosis in the 7MM in 2021.

Among the EU5 countries, the UK had the highest number of cystic fibrosis diagnosed prevalent cases in 2021.

The cystic fibrosis market reportproffers epidemiological analysis for the study period 20192032 in the 7MM segmented into:

Download the report to understand which factors are driving cystic fibrosis epidemiology trends @Cystic Fibrosis Epidemiological Insights

Cystic Fibrosis Treatment Market

Current cystic fibrosis medications focus on symptom relief, complication prevention, and, more recently, protein rectifiers to correct underlying structural and functional abnormalities. Inhaled antibiotics are used to treat chronic lung infections, mucolytics are used to reduce the viscosity of pulmonary mucus, pancreatic enzyme replacement therapy (PERT) is used to treat CF-associated exocrine pancreatic insufficiency (PPI), and CFTR modulators are used to improve CFTR function while addressing the underlying cause of the disease.

In addition to mucolytics like dornase alfa, hypertonic saline inhalation has been proposed as a therapy for increasing the hydration of airway surface liquid in cystic fibrosis patients. Pancreatic enzyme supplements, multivitamins (particularly fat-soluble vitamins), mucolytics, antibiotics (including inhaled, oral, or parenteral), bronchodilators, anti-inflammatory agents, and CFTR potentiators (e.g., ivacaftor) and correctors (e.g., elexacaftor, lumacaftor,tezacaftor) may be used to treat patients with cystic fibrosis.

The current cystic fibrosis treatment is primarily based on CFTR modulators and supportive therapies such as mucolytics, antibiotics, bronchodilators, and others. TRIKAFTA, SYMDEKO, ORKAMBI, and KALYDECO currently dominate the cystic fibrosis market.

Generally, a normal diet with additional energy and unrestricted fat intake is advised. To compensate for malabsorption and the increased energy demand of chronic inflammation, a high-energy and high-fat diet is recommended, along with supplemental vitamins (especially fat-soluble) and minerals. Sometimes cystic fibrosis causes issues that can only be resolved through surgery or another type of medical procedure.

To know more about cystic fibrosis medications, visit @Cystic Fibrosis Treatment Market

Cystic Fibrosis Pipeline Therapies and Key Companies

Learn more about the FDA-approved drugs for cystic fibrosis treatment @Cystic Fibrosis Drugs

Cystic Fibrosis Market Dynamics

The overall prevalence of cystic fibrosis is expected to rise over the forecast period, creating new opportunities for pharma players in the cystic fibrosis market. Moreover, existing therapies have room for label expansions to improve efficacy, propelling the cystic fibrosis market forward.

Furthermore, there are lucrative opportunities to address unmet therapeutic needs in the cystic fibrosis market regarding tolerability, drug resistance, dosage, and adverse effects. More combinational drugs with higher efficacy are needed.

With advancements in diagnostic tools and palliative care, the median cystic fibrosis life expectancy in the United States has risen from a few months to 46 years. Several cystic fibrosis drugs are currently being used to treat cystic fibrosis, with evidence ranging from randomized, double-blind, placebo-controlled clinical trials to anecdotal case reports. Many more are currently in the works. Pharma companies have been proactive in their research in the cystic fibrosis market, recognizing that the treatment has a long way to go.

However, due to the lack of significant competitors, the current cystic fibrosis market players will likely maintain their competitive positions throughout the study period. Despite improved outcomes, most cystic fibrosis patients die from pulmonary complications, making this one of the most significant underlying challenges in the cystic fibrosis treatment paradigm.

Moreover, the patient's pharmacological treatment history is complicated, with a plethora of drugs resulting in resistance and a constant shift in treatment regimens. Any generic drug entry will impede the cystic fibrosis market for branded drugs. Even Vertex has plans for generic cystic fibrosis medications.

Report Metrics

Details

Study Period

20192032

Coverage

7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Base Year

2021

Market CAGR

9%

Market Size in 2021

USD 7.1 Billion

Key Cystic Fibrosis Companies

Verona Pharmaceuticals, Eloxx Pharmaceuticals, Inc., Vertex Pharmaceuticals, Santhera Pharmaceuticals, Laurent Pharmaceuticals Inc., Krystal Biotech, Translate Bio, Novartis, Algi Pharma, Atlantic Healthcare, Calithera Biosciences, Horizon Therapeutics, Reveragen Biopharma, Spli Sense, GlaxoSmithKline, EmphyCorp, Galapagos NV, PathBio Analytics, AstraZeneca, AxentisPharma AG, and others

Key Cystic Fibrosis Therapies

Ensifentrine, ELX-02, VX-121/TEZ/ VX-561, POL6014 (Lonodelestat), LAU-7b, and others

Scope of the Cystic Fibrosis Market Report

Discover more about drugs for cystic fibrosis in development @Cystic Fibrosis Clinical Trials

Table of Contents

1.

Cystic Fibrosis Market Key Insights

2.

Cystic Fibrosis Market Report Introduction

3.

Cystic Fibrosis Market Overview at a Glance

4.

Cystic Fibrosis Market Executive Summary

5.

Disease Background and Overview

6.

Cystic Fibrosis Treatment and Management

7.

Cystic Fibrosis Epidemiology and Patient Population

8.

Patient Journey

9.

Cystic Fibrosis Marketed Drugs

10.

Cystic Fibrosis Emerging Drugs

11.

Seven Major Cystic Fibrosis Market Analysis

12.

Cystic Fibrosis Market Outlook

13.

Potential of Current and Emerging Therapies

14.

KOL Views

15.

Cystic Fibrosis Market Drivers

16.

Cystic Fibrosis Market Barriers

17.

Unmet Needs

18.

SWOT Analysis

19.

Appendix

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

Related Reports

Cystic Fibrosis Epidemiology Forecast

Cystic Fibrosis Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the cystic fibrosis epidemiology trends.

Cystic Fibrosis Pipeline

Cystic Fibrosis Pipeline Insight 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key cystic fibrosis companies, including Verona Pharmaceuticals, Eloxx Pharmaceuticals, Inc., Vertex Pharmaceuticals, Santhera Pharmaceuticals, among others.

Non-Cystic Fibrosis Bronchiectasis Market

Non-Cystic Fibrosis Bronchiectasis Market Insight, Epidemiology, and Market Forecast 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key non-cystic fibrosis bronchiectasis companies, including AstraZeneca, Insmed, Novartis, CSL Behring, Arrowhead Pharmaceuticals, among others.

Non-Cystic Fibrosis Bronchiectasis Pipeline

Non-Cystic Fibrosis Bronchiectasis Pipeline Insight 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key non-cystic fibrosis bronchiectasis companies, including AstraZeneca, Insmed, Novartis, CSL Behring, Arrowhead Pharmaceuticals, among others.

Non-Cystic Fibrosis Bronchiectasis Epidemiology

Non-Cystic Fibrosis Bronchiectasis Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the non-cystic fibrosis bronchiectasis epidemiology trends.

Read the original:

Cystic Fibrosis Market to Showcase Growth at a CAGR of 9% During the Forecast Period (2022-2032) | DelveInsight - PR Newswire